acitretin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
retinol derivatives	78	55079-83-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: acitretin acitretinoin etretin neotigason soriatane isoacitretin isoetretin	An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate. Molecular weight: 326.44 Formula: C21H26O3 CLOGP: 6.07 LIPINSKI: 1 HAC: 3 HDO: 1 TPSA: 46.53 ALOGS: -5.83 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

acitretin
acitretinoin
etretin
neotigason
soriatane
isoacitretin
isoetretin

An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate.

Molecular weight: 326.44
Formula: C21H26O3
CLOGP: 6.07
LIPINSKI: 1
HAC: 3
HDO: 1
TPSA: 46.53
ALOGS: -5.83
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
35	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	3.83 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	59 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Oct. 28, 1996	FDA	STIEFEL LABS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Psoriasis	885.31	22.45	388	9003	92304	56190372
Skin haemorrhage	237.10	22.45	78	9313	8335	56274341
Skin exfoliation	185.40	22.45	100	9291	36800	56245876
Neurologic neglect syndrome	157.58	22.45	42	9349	2156	56280520
Carotid artery thrombosis	156.72	22.45	42	9349	2202	56280474
Respiratory tract congestion	131.08	22.45	60	9331	15531	56267145
Personality disorder	122.12	22.45	42	9349	5131	56277545
Sneezing	118.75	22.45	56	9335	15504	56267172
Sinus congestion	118.19	22.45	56	9335	15668	56267008
Sinus disorder	103.53	22.45	56	9335	20678	56261998
Sensory loss	103.15	22.45	43	9348	8892	56273784
Hemiplegia	102.28	22.45	42	9349	8362	56274314
Affect lability	97.97	22.45	43	9348	10082	56272594
Motor dysfunction	97.50	22.45	42	9349	9415	56273261
Adjustment disorder	92.27	22.45	28	9363	2295	56280381
Psoriatic arthropathy	89.69	22.45	84	9307	73924	56208752
Coordination abnormal	85.90	22.45	42	9349	12579	56270097
Rhinorrhoea	85.47	22.45	73	9318	56964	56225712
Eating disorder	73.88	22.45	42	9349	17063	56265613
Muscle spasticity	70.42	22.45	43	9348	19917	56262759
Hemiparesis	67.50	22.45	43	9348	21447	56261229
Cutaneous T-cell lymphoma	60.78	22.45	18	9373	1357	56281319
Cystitis	58.10	22.45	55	9336	48983	56233693
Erythrodermic psoriasis	57.48	22.45	16	9375	966	56281710
Aphasia	56.20	22.45	44	9347	30371	56252305
Skin plaque	55.74	22.45	26	9365	7012	56275664
Influenza	54.37	22.45	73	9318	95188	56187488
Infected dermal cyst	53.98	22.45	13	9378	441	56282235
Pustular psoriasis	53.19	22.45	22	9369	4456	56278220
Skin lesion	52.63	22.45	41	9350	28094	56254582
Rhesus antigen positive	51.06	22.45	10	9381	124	56282552
Rash pustular	50.87	22.45	24	9367	6639	56276037
Oral lichen planus	50.37	22.45	13	9378	587	56282089
Influenza like illness	49.79	22.45	56	9335	60932	56221744
Erythema	49.19	22.45	91	9300	155848	56126828
Pruritus	47.74	22.45	138	9253	316485	55966191
Drug ineffective	46.60	22.45	286	9105	918703	55363973
Dysarthria	44.27	22.45	43	9348	39507	56243169
Dry skin	43.22	22.45	46	9345	47063	56235613
Arterial occlusive disease	42.89	22.45	20	9371	5390	56277286
Gangrene	42.43	22.45	20	9371	5520	56277156
Squamous cell carcinoma	40.63	22.45	22	9369	8126	56274550
Angina pectoris	40.23	22.45	35	9356	27941	56254735
Guttate psoriasis	40.22	22.45	10	9381	388	56282288
Dysphagia	38.16	22.45	57	9334	81890	56200786
Weaning failure	36.85	22.45	9	9382	324	56282352
Wrong technique in device usage process	36.56	22.45	15	9376	2975	56279701
Lichen planus	34.09	22.45	13	9378	2129	56280547
Blood immunoglobulin M decreased	32.83	22.45	10	9381	829	56281847
Skin fissures	32.17	22.45	20	9371	9553	56273123
Blood albumin increased	32.06	22.45	10	9381	898	56281778
Burning sensation	31.94	22.45	40	9351	48656	56234020
Pain of skin	31.44	22.45	19	9372	8627	56274049
Oesophageal stenosis	29.88	22.45	13	9378	2980	56279696
Immunoglobulins decreased	29.85	22.45	10	9381	1127	56281549
Tongue ulceration	29.13	22.45	13	9378	3166	56279510
Palmoplantar pustulosis	28.90	22.45	8	9383	473	56282203
Type IIb hyperlipidaemia	28.77	22.45	5	9386	30	56282646
Ichthyosis	27.52	22.45	5	9386	40	56282636
Nasopharyngitis	27.35	22.45	90	9301	220869	56061807
Inflammatory bowel disease	27.02	22.45	13	9378	3755	56278921
Toxicity to various agents	26.95	22.45	3	9388	224561	56058115
Increased bronchial secretion	26.46	22.45	10	9381	1597	56281079
Oesophageal ulcer	25.86	22.45	13	9378	4126	56278550
Injection site bruising	25.83	22.45	32	9359	38489	56244187
Sunburn	25.14	22.45	11	9380	2557	56280119
Arthritis	25.07	22.45	53	9338	99799	56182877
Keratoacanthoma	24.79	22.45	7	9384	445	56282231
Skin atrophy	24.75	22.45	13	9378	4517	56278159
Swelling	24.67	22.45	5	9386	239766	56042910
Tanning	24.52	22.45	5	9386	77	56282599
Onychalgia	24.42	22.45	8	9383	841	56281835
Face oedema	24.36	22.45	22	9369	18430	56264246
Blood immunoglobulin G decreased	23.48	22.45	10	9381	2176	56280500
Rebound psoriasis	23.20	22.45	5	9386	102	56282574
Inappropriate schedule of product administration	22.98	22.45	46	9345	83341	56199335
Mean cell haemoglobin increased	22.58	22.45	10	9381	2390	56280286

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Psoriasis	766.47	23.33	305	6204	46414	31644421
Drug ineffective	191.91	23.33	311	6198	395262	31295573
Vein rupture	187.38	23.33	41	6468	725	31690110
Skin plaque	172.87	23.33	54	6455	3961	31686874
Venous injury	108.16	23.33	22	6487	268	31690567
Pityriasis rubra pilaris	106.89	23.33	19	6490	104	31690731
Injection site haemorrhage	100.25	23.33	45	6464	9040	31681795
Erythrodermic psoriasis	89.56	23.33	23	6486	824	31690011
Injection site papule	83.52	23.33	18	6491	295	31690540
Psoriatic arthropathy	82.03	23.33	51	6458	19832	31671003
Cutaneous T-cell lymphoma	77.94	23.33	23	6486	1388	31689447
Dermatitis exfoliative generalised	77.78	23.33	28	6481	3171	31687664
Skin injury	76.74	23.33	24	6485	1763	31689072
Injection site swelling	74.73	23.33	38	6471	10049	31680786
Inappropriate schedule of product administration	70.14	23.33	68	6441	50755	31640080
Pain of skin	67.36	23.33	27	6482	4099	31686736
Therapeutic product effect incomplete	67.03	23.33	62	6447	43634	31647201
Hepatic fibrosis	62.03	23.33	25	6484	3849	31686986
Squamous cell carcinoma	61.37	23.33	34	6475	10677	31680158
Pruritus	59.27	23.33	98	6411	125069	31565766
Skin erosion	55.68	23.33	19	6490	1837	31688998
Drug intolerance	54.40	23.33	60	6449	51973	31638862
Granuloma annulare	53.92	23.33	11	6498	136	31690699
Hepatic cirrhosis	51.82	23.33	35	6474	15639	31675196
Hypercholesterolaemia	50.18	23.33	27	6482	8003	31682832
Squamous cell carcinoma of skin	49.43	23.33	29	6480	10145	31680690
Anti-cyclic citrullinated peptide antibody positive	48.39	23.33	16	6493	1404	31689431
Keratoacanthoma	47.72	23.33	13	6496	586	31690249
Phototherapy	47.06	23.33	8	6501	32	31690803
Joint ankylosis	44.27	23.33	14	6495	1066	31689769
Bone cyst	43.27	23.33	14	6495	1147	31689688
Pain in extremity	40.89	23.33	80	6429	116123	31574712
Treatment failure	40.83	23.33	46	6463	40746	31650089
Myalgia	39.92	23.33	63	6446	77195	31613640
Hyperkeratosis	37.90	23.33	17	6492	3403	31687432
Muscular weakness	34.67	23.33	54	6455	65394	31625441
Malignant melanoma stage I	34.35	23.33	7	6502	86	31690749
Basal cell carcinoma	34.23	23.33	29	6480	18150	31672685
Induration	33.95	23.33	11	6498	905	31689930
Osteolysis	33.85	23.33	14	6495	2301	31688534
Botryomycosis	33.57	23.33	6	6503	34	31690801
Hidradenitis	32.54	23.33	11	6498	1033	31689802
Neuroendocrine tumour of the lung metastatic	32.46	23.33	7	6502	115	31690720
Macule	31.79	23.33	11	6498	1108	31689727
Emotional distress	31.43	23.33	25	6484	14331	31676504
Skin exfoliation	31.13	23.33	31	6478	23843	31666992
Red blood cell sedimentation rate abnormal	30.26	23.33	14	6495	3008	31687827
Hand deformity	30.15	23.33	14	6495	3033	31687802
Retinal disorder	29.94	23.33	10	6499	905	31689930
Decreased immune responsiveness	28.68	23.33	11	6498	1484	31689351
Insomnia	27.12	23.33	60	6449	94776	31596059
Acute kidney injury	26.81	23.33	12	6497	279702	31411133
Toxicity to various agents	26.80	23.33	3	6506	181484	31509351
Alanine aminotransferase abnormal	26.65	23.33	14	6495	3953	31686882
Myasthenia gravis	26.40	23.33	14	6495	4029	31686806
Bone erosion	25.71	23.33	13	6496	3390	31687445
Erythema	25.43	23.33	53	6456	80352	31610483
Gastrointestinal infection	24.15	23.33	14	6495	4786	31686049
Gastrointestinal tube insertion	23.80	23.33	9	6500	1168	31689667
Diabetes mellitus	23.76	23.33	36	6473	42520	31648315
Hypereosinophilic syndrome	23.49	23.33	6	6503	210	31690625

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Psoriasis	1435.48	19.03	593	14143	97840	70815868
Skin haemorrhage	231.31	19.03	85	14651	10095	70903613
Drug ineffective	201.48	19.03	533	14203	939219	69974489
Skin exfoliation	177.62	19.03	116	14620	48510	70865198
Skin plaque	165.88	19.03	66	14670	9717	70903991
Vein rupture	154.50	19.03	41	14695	1652	70912056
Neurologic neglect syndrome	145.10	19.03	42	14694	2339	70911369
Carotid artery thrombosis	142.32	19.03	42	14694	2504	70911204
Cutaneous T-cell lymphoma	124.90	19.03	38	14698	2515	70911193
Psoriatic arthropathy	120.36	19.03	103	14633	64668	70849040
Erythrodermic psoriasis	117.43	19.03	33	14703	1651	70912057
Respiratory tract congestion	111.46	19.03	60	14676	17593	70896115
Personality disorder	110.23	19.03	42	14694	5506	70908202
Squamous cell carcinoma	107.48	19.03	55	14681	14549	70899159
Pityriasis rubra pilaris	106.05	19.03	19	14717	108	70913600
Sneezing	102.53	19.03	56	14680	16895	70896813
Sinus congestion	101.24	19.03	56	14680	17317	70896391
Sinus disorder	99.35	19.03	57	14679	18902	70894806
Injection site haemorrhage	90.96	19.03	60	14676	25467	70888241
Affect lability	88.83	19.03	43	14693	10103	70903605
Venous injury	88.52	19.03	22	14714	680	70913028
Dermatitis exfoliative generalised	87.36	19.03	37	14699	6377	70907331
Sensory loss	86.92	19.03	44	14692	11375	70902333
Pruritus	84.62	19.03	207	14529	345353	70568355
Inappropriate schedule of product administration	83.17	19.03	107	14629	107448	70806260
Motor dysfunction	78.55	19.03	43	14693	13027	70900681
Adjustment disorder	77.91	19.03	28	14708	3116	70910592
Hemiplegia	73.40	19.03	42	14694	13853	70899855
Rhinorrhoea	72.83	19.03	79	14657	66292	70847416
Keratoacanthoma	72.19	19.03	20	14716	949	70912759
Skin lesion	71.08	19.03	61	14675	38399	70875309
Pain of skin	67.91	19.03	36	14700	10230	70903478
Coordination abnormal	67.75	19.03	42	14694	16024	70897684
Injection site papule	65.51	19.03	18	14718	828	70912880
Pustular psoriasis	63.91	19.03	27	14709	4623	70909085
Toxicity to various agents	63.64	19.03	4	14732	382168	70531540
Muscle spasticity	62.30	19.03	43	14693	19646	70894062
Eating disorder	62.19	19.03	42	14694	18523	70895185
Influenza	54.16	19.03	90	14646	113610	70800098
Erythema	53.54	19.03	124	14612	199439	70714269
Cystitis	53.46	19.03	57	14679	46884	70866824
Therapeutic product effect incomplete	53.27	19.03	92	14644	119790	70793918
Rhesus antigen positive	48.87	19.03	10	14726	124	70913584
Muscular weakness	48.67	19.03	96	14640	138240	70775468
Hemiparesis	44.58	19.03	43	14693	31426	70882282
Hyperkeratosis	44.49	19.03	24	14712	7060	70906648
Skin erosion	44.38	19.03	20	14716	3996	70909712
Aphasia	43.16	19.03	49	14687	43200	70870508
Squamous cell carcinoma of skin	43.15	19.03	29	14707	12683	70901025
Phototherapy	41.10	19.03	7	14729	28	70913680
Rash pustular	41.07	19.03	26	14710	10282	70903426
Induration	40.95	19.03	15	14721	1761	70911947
Oral lichen planus	40.46	19.03	12	14724	727	70912981
Granuloma annulare	39.04	19.03	11	14725	555	70913153
Onychalgia	39.00	19.03	12	14724	824	70912884
Joint ankylosis	38.97	19.03	14	14722	1555	70912153
Influenza like illness	37.00	19.03	56	14680	65275	70848433
Guttate psoriasis	36.89	19.03	10	14726	437	70913271
Acute kidney injury	36.81	19.03	27	14709	474597	70439111
Skin fissures	36.56	19.03	25	14711	11245	70902463
Infected dermal cyst	35.07	19.03	12	14724	1155	70912553
Rebound psoriasis	34.13	19.03	8	14728	192	70913516
Injection site swelling	33.42	19.03	43	14693	43114	70870594
Arthritis	33.25	19.03	67	14669	97913	70815795
Dry skin	33.18	19.03	49	14687	55882	70857826
Neuroendocrine tumour of the lung metastatic	32.32	19.03	7	14729	116	70913592
Arterial occlusive disease	32.03	19.03	20	14716	7722	70905986
Hypercholesterolaemia	31.97	19.03	28	14708	18089	70895619
Malignant melanoma stage I	31.47	19.03	7	14729	132	70913576
Myalgia	31.25	19.03	91	14645	167801	70745907
Skin injury	31.13	19.03	14	14722	2784	70910924
Nasopharyngitis	30.94	19.03	109	14627	222097	70691611
Bone cyst	30.77	19.03	14	14722	2860	70910848
Gangrene	30.73	19.03	20	14716	8289	70905419
Pain in extremity	30.57	19.03	142	14594	327940	70585768
Death	30.20	19.03	37	14699	510024	70403684
Hypotension	30.07	19.03	24	14712	404357	70509351
Dyslipidaemia	29.94	19.03	21	14715	9839	70903869
Immunoglobulins decreased	29.07	19.03	11	14725	1413	70912295
Macule	28.88	19.03	13	14723	2590	70911118
Weaning failure	28.73	19.03	9	14727	656	70913052
Wrong technique in device usage process	28.65	19.03	14	14722	3354	70910354
Neutropenia	28.46	19.03	9	14727	257147	70656561
Skin atrophy	28.27	19.03	16	14720	5163	70908545
Osteolysis	28.07	19.03	14	14722	3505	70910203
Skin disorder	27.94	19.03	33	14703	30324	70883384
Blood immunoglobulin M decreased	27.84	19.03	10	14726	1110	70912598
Type IIb hyperlipidaemia	27.67	19.03	5	14731	30	70913678
Dysphagia	26.87	19.03	67	14669	112767	70800941
Anaemia	26.34	19.03	27	14709	403396	70510312
Lichen planus	26.04	19.03	12	14724	2523	70911185
Palmoplantar pustulosis	25.98	19.03	8	14728	551	70913157
Blood albumin increased	25.46	19.03	10	14726	1420	70912288
Somnolence	24.85	19.03	7	14729	215599	70698109
Botryomycosis	24.66	19.03	5	14731	59	70913649
Cataract	23.78	19.03	42	14694	55603	70858105
Tanning	23.37	19.03	5	14731	78	70913630
Cutaneous symptom	23.35	19.03	7	14729	440	70913268
Inflammatory bowel disease	23.34	19.03	14	14722	5032	70908676
Burning sensation	22.71	19.03	40	14696	52830	70860878
Blood pressure increased	22.49	19.03	88	14648	188429	70725279
Psoriasis area severity index increased	21.83	19.03	5	14731	108	70913600
Infusion related reaction	21.70	19.03	7	14729	197527	70716181
Tongue ulceration	21.66	19.03	12	14724	3719	70909989
Dysarthria	21.59	19.03	43	14693	62270	70851438
Dehydration	21.56	19.03	10	14726	226132	70687576
Dizziness	21.34	19.03	40	14696	464101	70449607
Hepatic cirrhosis	21.29	19.03	29	14707	30702	70883006
Hidradenitis	21.13	19.03	11	14725	3011	70910697
Oesophageal stenosis	20.86	19.03	12	14724	3992	70909716
Hyponatraemia	20.82	19.03	4	14732	160083	70753625
Tonsil cancer	20.81	19.03	8	14728	1073	70912635
Thrombocytopenia	20.68	19.03	12	14724	239098	70674610
Ichthyosis	20.66	19.03	5	14731	138	70913570
Hepatic fibrosis	20.56	19.03	14	14722	6253	70907455
Cerebrovascular accident	20.49	19.03	71	14665	143399	70770309
Platelet count decreased	20.14	19.03	6	14730	178216	70735492
Seizure	20.10	19.03	6	14730	177956	70735752
Constipation	20.01	19.03	14	14722	252424	70661284
Tremor	20	19.03	4	14732	155620	70758088
Diffuse idiopathic skeletal hyperostosis	19.67	19.03	4	14732	48	70913660
Sunburn	19.41	19.03	11	14725	3560	70910148
Basal cell carcinoma	19.23	19.03	29	14707	33669	70880039
Decreased appetite	19.20	19.03	21	14715	304759	70608949

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	D05BB02	DERMATOLOGICALS ANTIPSORIATICS ANTIPSORIATICS FOR SYSTEMIC USE Retinoids for treatment of psoriasis
FDA CS	M0018962	Retinoids
FDA EPC	N0000175607	Retinoid
CHEBI has role	CHEBI:50176	keratolytic drugs
MeSH PA	D003879	Dermatologic Agents
MeSH PA	D007641	Keratolytic Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Severe Recalcitrant Psoriasis	indication
Lichen planus	off-label use	4776004	DOID:9201
Keratosis follicularis	off-label use	48611009	DOID:2734
Lamellar ichthyosis	off-label use	205550003
Ichthyosiform erythroderma	off-label use	268282005
Primary cutaneous T-cell lymphoma	off-label use	400122007
Alcoholism	contraindication	7200002
Hypercholesterolemia	contraindication	13644009
Depressive disorder	contraindication	35489007
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Night blindness	contraindication	65194006	DOID:8499
Benign intracranial hypertension	contraindication	68267002	DOID:11459
Diabetes mellitus	contraindication	73211009	DOID:9351
Premature epiphyseal closure	contraindication	89493005
Liver function tests abnormal	contraindication	166603001
Hypoalphalipoproteinemia	contraindication	190785000
Acute pancreatitis	contraindication	197456007	DOID:2913
Hypertrophy of bone	contraindication	203514008	DOID:205
Drug-induced hepatitis	contraindication	235876009
Pregnancy, function	contraindication	289908002
Hypertriglyceridemia	contraindication	302870006
Cardiovascular event risk	contraindication	395112001
Visual impairment	contraindication	397540003
Breastfeeding (mother)	contraindication	413712001
Obesity	contraindication	414916001	DOID:9970
Psychiatric Disturbance	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.17	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Retinoic acid receptor alpha	Nuclear hormone receptor	P10276	RARA_HUMAN	AGONIST			WOMBAT-PK	CHEMBL
Retinoic acid receptor gamma	Nuclear hormone receptor	P13631	RARG_HUMAN	AGONIST			CHEMBL	CHEMBL
Bile salt export pump	Transporter	O95342	ABCBB_HUMAN		IC50	4.74	CHEMBL
Bile salt export pump	Transporter		ABCBB_RAT		IC50	4.71	CHEMBL

External reference:

ID	Source
4021061	VUID
N0000148524	NUI
D02754	KEGG_DRUG
16818	RXNORM
C0050559	UMLSCUI
CHEBI:50173	CHEBI
CHEMBL1131	ChEMBL_ID
DB00459	DRUGBANK_ID
D017255	MESH_DESCRIPTOR_UI
5284513	PUBCHEM_CID
7598	IUPHAR_LIGAND_ID
5530	INN_ID
LCH760E9T7	UNII
004121	NDDF
108914001	SNOMEDCT_US
386938006	SNOMEDCT_US
4021061	VANDF
69427-46-9	SECONDARY_CAS_RN
11379	MMSL
117161	MMSL
4128	MMSL
d03836	MMSL

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1135	CAPSULE	10 mg	ORAL	ANDA	24 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1135	CAPSULE	10 mg	ORAL	ANDA	24 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1135	CAPSULE	10 mg	ORAL	ANDA	24 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1136	CAPSULE	25 mg	ORAL	ANDA	24 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1136	CAPSULE	25 mg	ORAL	ANDA	24 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1136	CAPSULE	25 mg	ORAL	ANDA	24 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1138	CAPSULE	17.50 mg	ORAL	ANDA	24 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1138	CAPSULE	17.50 mg	ORAL	ANDA	24 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1138	CAPSULE	17.50 mg	ORAL	ANDA	24 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1750	CAPSULE	10 mg	ORAL	ANDA	17 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1751	CAPSULE	17.50 mg	ORAL	ANDA	17 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1752	CAPSULE	22.50 mg	ORAL	ANDA	17 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1753	CAPSULE	25 mg	ORAL	ANDA	17 sections
SORIATANE	HUMAN PRESCRIPTION DRUG LABEL	1	0145-0090	CAPSULE	10 mg	ORAL	NDA	27 sections
SORIATANE	HUMAN PRESCRIPTION DRUG LABEL	1	0145-0091	CAPSULE	25 mg	ORAL	NDA	27 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0378-7020	CAPSULE	10 mg	ORAL	ANDA	28 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0378-7020	CAPSULE	10 mg	ORAL	ANDA	28 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0378-7023	CAPSULE	25 mg	ORAL	ANDA	28 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0378-7023	CAPSULE	25 mg	ORAL	ANDA	28 sections
ACITRETIN	HUMAN PRESCRIPTION DRUG LABEL	1	42291-086	CAPSULE	10 mg	ORAL	ANDA	25 sections
ACITRETIN	HUMAN PRESCRIPTION DRUG LABEL	1	42291-087	CAPSULE	17.50 mg	ORAL	ANDA	25 sections
ACITRETIN	HUMAN PRESCRIPTION DRUG LABEL	1	42291-088	CAPSULE	25 mg	ORAL	ANDA	25 sections
ACITRETIN	HUMAN PRESCRIPTION DRUG LABEL	1	42794-080	CAPSULE	10 mg	ORAL	ANDA	25 sections
ACITRETIN	HUMAN PRESCRIPTION DRUG LABEL	1	42794-081	CAPSULE	17.50 mg	ORAL	ANDA	25 sections
ACITRETIN	HUMAN PRESCRIPTION DRUG LABEL	1	42794-083	CAPSULE	25 mg	ORAL	ANDA	25 sections
ACITRETIN	HUMAN PRESCRIPTION DRUG LABEL	1	66993-894	CAPSULE	10 mg	ORAL	NDA authorized generic	16 sections
ACITRETIN	HUMAN PRESCRIPTION DRUG LABEL	1	66993-896	CAPSULE	25 mg	ORAL	NDA authorized generic	16 sections